Physician profile
Paul E Kovatis
NPI 1669475083
$2,291.69
in general payments reported to CMS, 2019-2025
32 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $276 · 2021: $336 · 2022: $308 · 2023: $140 · 2024: $178 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $641.28 | 2020-2025 | Monovisc, Milagro, Healix Knotless Peek |
| Amgen INC. | $350.70 | 2019-2025 | Evenity |
| Zimmer Biomet Holdings, INC. | $186.45 | 2022-2024 | Identity |
| Stryker Corporation | $151.16 | 2019 | |
| Ucb, INC. | $116.39 | 2025 | Bimzelx |
| Djo, LLC | $78.50 | 2025 | Cmf |
| Globus Medical, INC. | $77.68 | 2021-2022 | |
| Radius Health, INC. | $66.61 | 2020-2025 | Tymlos |
| Paragon 28, INC. | $58.74 | 2019-2022 | |
| Kerecis Limited | $46.06 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Zyla Life Sciences, INC. | $40.75 | 2020 | |
| Horizon Therapeutics Plc | $38.39 | 2019-2020 | |
| Treace Medical Concepts, INC. | $37.21 | 2025 | |
| Wright Medical Technology, INC. | $34.70 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.63 | 2025 | Entyvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $31.92 | 2023 | Trivisc Sodium Hyaluronate |
| Sanofi-Aventis U.S. LLC | $26.05 | 2020-2021 | |
| Integra Lifesciences Corporation | $22.05 | 2020 | |
| Kci USA, INC. | $21.86 | 2021 | |
| Fidia Pharma USA INC. | $21.30 | 2020 | |
| Glaxosmithkline, LLC. | $20.96 | 2020 | |
| Appliedvr INC | $20.02 | 2025 | Relievrx |
| Mallinckrodt Hospital Products INC. | $19.23 | 2025 | Acthar |
| Phathom Pharmaceuticals, INC. | $19.00 | 2025 | Voquezna |
| Lilly USA, LLC | $18.36 | 2025 | Omvoh |
| Seapearl East, INC | $18.22 | 2023 | |
| Ani Pharmaceuticals, INC. | $16.90 | 2025 | Purified Cortrophin Gel |
| Orthogenrx INC. | $16.64 | 2019 | |
| Synergy Orthopedics, LLC | $15.84 | 2022 | |
| Next Science LLC | $15.67 | 2021 | |
| Smith+Nephew, INC. | $15.57 | 2021 | |
| Collegium Pharmaceutical, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kovatis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.